News
News from the BioCity Campus

General meeting of biosaxony eV 2020

On September 09th, the members of biosaxony eV met in the Center for Regenerative Therapies Dresden and in the network for the hybrid general meeting. In addition to various other items, the election of a new board was on the agenda.

 

As a groundbreaking decision, it was decided to expand the work of the network more into the area of ​​healthcare in the future. The background to this decision is the fact that the majority of biosaxony members develop products and services for this market and therefore need a close relationship with clinics, providers and health insurance companies for a successful market entry. Several biosaxonys projects are already geared towards building a bridge to this market. In this way, biosaxony eV will in future cover the sectors of biotechnology, medical technology and healthcare.

As chairman of the board, Dr. Oliver Uecke from Lipotype GmbH. He is the successor to Prof. Dr. Frank Emmrich, who will continue to be a member of the Management Board. André Hofmann (biosaxony Management GmbH) will continue to act as Deputy Chairman of the Board. The task of treasurer will also continue to be carried out by Christian Wotjak from KPMG AG.

In order to reflect the new areas of responsibility of the association in the future in the board of directors, this is now expanded to nine members. In addition to dr. Ekkehard Nolting (Battke Grünberg Rechtsanwälte PartGmbB) and Sebastian Alexander (VivoSensMedical GmbH), who had already worked as board members in the previous period, have now also been appointed to Prof. Dr. Thomas Neumuth (Innovation Center Computer Assisted Surgery – ICCAS), Prof. Dr. Martin Bornhäuser (Medical Clinic I, University Hospital Dresden) and Prof. Dr. Dirk Winkler (Clinic for Neurosurgery, University Hospital Leipzig) was elected to the board.

biosaxony eV would like to thank its board members for their valuable work and commitment and looks forward to the years to come. The new CEO, Dr. Oliver Uecke, with a view to the LifeScience Forum Sachsen prior to the General Assembly, gives an outlook on the coming term of office: “This year we are celebrating 20 years of Biotechnology Offensive Saxony. The Saxon biotech offensive in 2000 was bold, forward-looking and successful. Biotech research in Saxony has arrived on the international map. In addition to biotechnology, biosaxony has also focused on medical technology and health care in recent years. In the future, it will be important to continue driving industry growth with this setup.”

About biosaxony

biosaxony is the all-Saxon association for biotechnology and medical technology. Its members include companies, scientific institutions as well as stakeholders and suppliers in the industry. The network bundles the strengths of all member companies and represents their interests in politics and the public. Tasks of the cluster include the initiation of projects between business and science, the provision of services and know-how as well as the presentation of regional competencies in order to support the value-adding expansion of these cross-sectional technologies and to strengthen the economic region of Saxony. In addition, the promotion of young innovative companies is one of the main concerns of the network.

Source: Media information from biosaxony eV from September 29.09.2020th, XNUMX


previous news

Saxon innovations meet capital

Saxony is home to many promising start-ups. With the innovation platform futureSAX and the Corona Start-up Aid Fund, the Free State supports their development and visibility on the capital market - especially in challenging times. A model with exemplary character, as evidenced by the great interest shown by investors and current examples of success.

NextNews

54th Annual Meeting of the German Society for Biomedical Engineering - BMT 2020

This year's 54th annual conference of the German Society for Biomedical Engineering (BMT) will be the ideal online forum for networking and the exchange of interests between researchers, users and companies in the field of biomedical engineering.